Abeona Therapeutics Inc Book/Share
What is the Book/Share of Abeona Therapeutics Inc?
The Book/Share of Abeona Therapeutics Inc is 1.62
What is the definition of Book/Share?
Book value per share is a company’s assets minus liabilities divided by the number of shares outstanding.
mrq (most recent quarter)
The book value of a company is the value of its assets according to its balance sheet account balance. For assets, the value is based on the original cost of the asset less any depreciation, amortization or impairment costs made against the asset. Traditionally, a company's book value is its total assets minus intangible assets and liabilities. However, in practice, depending on the source of the calculation, book value may variably include goodwill, intangible assets, or both. The value inherent in its workforce, part of the intellectual capital of a company, is always ignored. The book value of a company may be also referred as with the term net asset value.
The book value per share is the the balance sheet equity value divided by the number of shares outstanding at the date of the balance sheet. Book value per share can be used to generate a measure of comprehensive earnings, when the opening and closing values are reconciled. The sale of shares/units by a business increases the total book value. Book value per share will increase if the additional shares are issued at a price higher than the pre-existing book value per share. The purchase of its own shares by a business will decrease total book value. Book value per share will decrease if more is paid for them than was received when originally issued. Dividends paid out will decrease book value per share value.
Book/Share of companies in the Health Care sector on NASDAQ compared to Abeona Therapeutics Inc
What does Abeona Therapeutics Inc do?
abeona therapeutics inc. (nasdaq: $abeo), is a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare genetic diseases. abeona was forged from the company’s close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases. abeona's lead programs include abo-102 (aav-sgsh), an adeno-associated virus (aav) based gene therapy for sanfilippo syndrome type a (mps iiia) and eb-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (rdeb). abeona is also developing abo-101 (aav-naglu) for sanfilippo syndrome type b (mps iiib), abo-201 (aav-cln3) gene therapy for juvenile batten disease (jncl), abo-202 (aav-cln1) for treatment of infantile batten disease (incl), eb-201 for epidermolysis bullosa (eb), abo-301 (aav-fancc) for fanconi anemia (fa) disorder and abo-302 using a novel crispr/cas9-based gene editing approach to gene t
Companies with book/share similar to Abeona Therapeutics Inc
- Future Generation Global Investment has Book/Share of 1.62
- Global Value Fund has Book/Share of 1.62
- Cia Energetica DE Minas Gerais - Cemig has Book/Share of 1.62
- Dongjiang Environmental has Book/Share of 1.62
- Homeland Interactive Technology has Book/Share of 1.62
- Boat Rocker Media has Book/Share of 1.62
- Abeona Therapeutics Inc has Book/Share of 1.62
- Uranium Royalty has Book/Share of 1.63
- Medicure has Book/Share of 1.63
- Greenpro Capital has Book/Share of 1.63
- Tse Sui Luen Jewellery (International) has Book/Share of 1.63
- Trainline Plc has Book/Share of 1.63
- AWN has Book/Share of 1.63